Fever after Gemcitabine Administration is a Poor Prognostic Factor in Patients with Metastatic Urothelial Carcinoma : Multicenter Retrospective Study
Gemcitabine (GEM) is currently a standard chemotherapeutic agent for metastatic urothelial carcinoma (mUC). Fever isknown to be an adverse effect of GEM ; however, itsincidence, etiology and clinical significance have not been evaluated. The objective of this study was to elucidate the characteristi...
Ausführliche Beschreibung
Bibliographische Detailangaben
| Veröffentlicht in: | Hinyokika kiyo. Acta urologica Japonica. - 1962. - 67(2021), 5 vom: 01. Mai, Seite 181-185
|
|---|
| 1. Verfasser: |
Maehana, Takeshi
(VerfasserIn) |
|---|
| Weitere Verfasser: |
Tanaka, Toshiaki,
Shindo, Tetsuya,
Takahashi, Atushi,
Ito, Naoki,
Taguchi, Keisuke,
Hotta, Hiroshi,
Tachiki, Hitoshi,
Matsukawa, Masanori,
Adachi, Hideki,
Kato, Ryuichi,
Kunishima, Yasuharu,
Masumori, Naoya |
|---|
| Format: | Online-Aufsatz
|
|---|
| Sprache: | Japanese |
|---|
| Veröffentlicht: |
2021
|
|---|
| Zugriff auf das übergeordnete Werk: | Hinyokika kiyo. Acta urologica Japonica
|
|---|
| Schlagworte: | Journal Article
Multicenter Study
Deoxycytidine
0W860991D6
Cisplatin
Q20Q21Q62J
Gemcitabine |
|---|